Abstract Details
|
Louis Chicoine
PRESENTER |
No disclosure on file |
| Roshan L. Koul, MD, DM, FRCPCH (Sultan Qaboos University Hospital) | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Danielle A. Griffin | Ms. Griffin has stock in Sarepta Therapeutics. Ms. Griffin has received intellectual property interests from a discovery or technology relating to health care. |
| No disclosure on file | |
| K. Reed Clark, PhD | No disclosure on file |
| Zarife F. Sahenk, MD, PhD, FÂ鶹´«Ã½Ó³» (The Research Institute at Nationwide Childrens.org) | Dr. Sahenk has nothing to disclose. |
| Christopher Walker, PhD (The Research Institute) | No disclosure on file |
| Jerry R. Mendell, MD, FÂ鶹´«Ã½Ó³» (The Research Institute at Nationwide Children's Hospital) | Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta. |
| Louise R. Rodino-Klapac (Sarepta Therapeutics) | Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care. |